SCHEMBL24906359

SCHEMBL24906359

CCOC(=O)c1c(C(F)(F)F)c(C(C)(F)F)nn1CC1CC(F)(F)C1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
PLAT P00750 1/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 1/20 0.33
CNR2 P34972 1/20 0.31
MAPT P10636 3/20 0.31
POLB P06746 1/20 0.31
SLC34A1 Q06495 1/20 0.31
ADORA2B P29275 1/20 0.30
ATM Q13315 1/20 0.30
TSHR P16473 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
RORC P51449 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27243079 0.90 KDM4E (0.33) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL24758408 0.88 ALDH1A1 (0.32) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL24757316 0.85 LMNA (0.30) LMNA
SCHEMBL24906236 0.85 LMNA (0.34) KDM4EALDH1A1HPGDPLATKMT2A
SCHEMBL27243087 0.85 KMT2A (0.32) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL30141544 0.83 MAPT (0.34) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL30951782 0.82 LMNA (0.33) KDM4EALDH1A1HPGDLMNACNR2
SCHEMBL30951783 0.82 LMNA (0.33) KDM4EALDH1A1HPGDLMNACNR2
SCHEMBL24906332 0.82 LMNA (0.33) KDM4EALDH1A1HPGDLMNACNR2
SCHEMBL24906342 0.80 LMNA (0.32) KDM4EALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126648-A1 SULFOXIMINES AS INHIBITORS OF NaV1.8 Grünenthal GmbH (DE) 2024-06-20 WO disclosed
WO-2024126648-A1 SULFOXIMINES AS INHIBITORS OF NaV1.8 Grünenthal GmbH (DE) 2024-06-20 WO disclosed
EP-4385984-A1 PYRIDINE-N-OXIDES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 EP disclosed
EP-4385984-A1 PYRIDINE-N-OXIDES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 EP disclosed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 US disclosed
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES GRUENENTHAL GMBH (DE) 2023-01-26 US disclosed
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES GRUENENTHAL GMBH (DE) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999699-B2 Substituted pyrazole amides SCN8A, SCN1A, SCN7A KDM4E 2803/4885ALDH1A1 834/4885HPGD 977/4885
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES SCN8A, SCN1A, SCN7A KDM4E 2803/4885ALDH1A1 834/4885HPGD 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.